ABBV vs REPL

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Replimune (REPL) now faces a significantly heightened risk profile following the FDA's second Complete Response Letter (CRL) for RP1 in anti-PD-1-failed melanoma. This crucial setback invalidates the primary near-term catalyst and severely delays commercialization, pushing out any potential 10x growth within the 3-5 year timeframe. The market has reacted with a ~60% stock decline, widespread analy...